Radiopharm’s research elevated to prestigious publication

Radiopharm Theranostics’ research into early detection of a variety of cancers was recognized after publication of its article in the prestigious medical journal Cancers. The pharmaceutical company has developed a line of world-class medical products apparently capable of tracking and tracing the movement of cancer molecules. The technology has also demonstrated a “remarkable” ability to attack a range of different cancer molecules.

Radiopharm’s approach focuses on so-called avêžµ6 integrins which are present in a variety of cancers, including cancer of the pancreas, head and neck, and certain types of lung cancer. The technology seeks to track the movement of target molecules that are illuminated during positron emission tomography, or “PET”.

The conclusion drawn in the article indicated that of all the integrins, avêžµ6 is “arguably the most promising target structure for radiotheranosis”, noting its broad clinical significance in oncology as well as fibrotic diseases, which may include syndromes linked to the disease. COVID-19. While studies over the past two decades in the field of radiotheranosis research have focused on an avêžµ3 subtype, Radiopharm appears to be making serious progress in emphasizing the effectiveness of integrin targeting avêžµ6.

Radiopharm is a new kid on the ASX block having been listed only a few weeks ago. However, despite its short tenure as a state-owned company, it has already generated quite a bit of talk in the streets given the 25 years of experience of its highly successful executive chairman, Paul Hopper.

One of Hopper’s most significant accomplishments includes founding Imugene, a multibillion-dollar market capitalization company, of which he remains the largest shareholder. He also founded ASX-listed Chimeric Therapeutics and serves on the boards of Prescient, Polynoma and Suda Pharmaceuticals. In 2018, Hopper sold another of his successful companies, Viralytics, to Merck for $ 500 million.

To be published in Cancers is a great recognition of Professor Notni and his potentially transformational work.

A phase 1 compassionate-use diagnostic approach is underway in Germany, targeting pancreatic and head and neck cancer and has so far included 15 patients. As part of our sponsored research agreement with Prof. Notni and his company, TRIMT GmbH, we look forward to developing the technology towards therapeutic application in due course.

While the public biopharmacy sector is currently experiencing a strong resurgence amid the COVID-19 crisis, Radiopharm appears well positioned to take advantage of the booming market. Be published in a reputable magazine such as Cancers Not only shines a light on the company’s recent successes, but also elevates its reputation among its peers as an emerging leader in the field.

Is Your ASX Listed Company Doing Something Interesting? Contact: [email protected]

Comments are closed.